Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

8 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Lisocabtagene Maraleucel for Relapsed/Refractory Large B-Cell Lymphoma: A Cell Therapy Consortium Real-World Analysis.
Riedell PA, Grady CB, Nastoupil LJ, Luna De Abia A, Ahmed N, Maziarz RT, Hu M, Brower J, Hwang WT, Schuster SJ, Chen AI, Oluwole OO, Bachanova V, McGuirk JP, Perales MA, Bishop MR, Porter DL. Riedell PA, et al. Among authors: luna de abia a. Blood Adv. 2024 Dec 10:bloodadvances.2024014164. doi: 10.1182/bloodadvances.2024014164. Online ahead of print. Blood Adv. 2024. PMID: 39657136
Dynamics of Immune Reconstitution and Impact on Outcomes Across CAR-T Cell Products in Large B-Cell Lymphoma.
Luan D, DeWolf S, Fei T, Raj S, Shah GL, Lareau CA, Alhomoud M, Salles G, Rivas-Delgado A, Rejeski K, Park JH, Luttwak E, Luna de Abia A, Corona M, Ntrivalas E, Cassanello G, Gomez-Llobell M, Parascondola A, Scordo M, Hsu KC, Palomba ML, Perales MA, Shouval R. Luan D, et al. Among authors: luna de abia a. Blood Cancer Discov. 2024 Dec 12. doi: 10.1158/2643-3230.BCD-24-0163. Online ahead of print. Blood Cancer Discov. 2024. PMID: 39666878
Cancer cachexia and weight loss before CAR T-cell therapy for lymphoma are independently associated with poor outcomes.
Valtis YK, Devlin S, Shouval R, Rejeski K, Corona M, Luna De Abia A, Rivas-Delgado A, Luttwak E, Cassanello G, Landego I, Schöder H, Bedmutha A, Boardman A, Shah GL, Scordo M, Perales MA, Salles G, Palomba ML, Shah UA, Park JH. Valtis YK, et al. Among authors: luna de abia a. Blood Adv. 2025 Jan 14;9(1):151-161. doi: 10.1182/bloodadvances.2024014555. Blood Adv. 2025. PMID: 39471490 Free PMC article.
Shift from Widespread to Tailored Antifungal Prophylaxis in Lymphoma Patients Treated with CD19 CAR T Cell Therapy: Results from a Large Retrospective Cohort.
Melica G, Luna de Abia A, Shah GL, Devlin S, Corona M, Fein J, Dahi PB, Giralt SA, Lin RJ, Palomba ML, Parascondola A, Park J, Salles G, Saldia A, Scordo M, Shouval R, Perales MA, Seo SK. Melica G, et al. Among authors: luna de abia a. Transplant Cell Ther. 2025 Jan;31(1):36-44. doi: 10.1016/j.jtct.2024.10.010. Epub 2024 Oct 22. Transplant Cell Ther. 2025. PMID: 39448032 Free article.
CNS bridging radiotherapy achieves rapid cytoreduction before CAR T-cell therapy for aggressive B-cell lymphomas.
Cederquist GY, Schefflein J, Devlin SM, Shah GL, Shouval R, Hubbeling H, Tringale K, Alarcon Tomas A, Fregonese B, Hajj C, Boardman A, Luna De Abia A, Corona M, Cassanello G, Dahi PB, Lin RJ, Ghione P, Salles G, Perales MA, Palomba ML, Falchi L, Scordo M, Grommes C, Yahalom J, Imber BS. Cederquist GY, et al. Among authors: luna de abia a. Blood Adv. 2024 Oct 8;8(19):5192-5199. doi: 10.1182/bloodadvances.2024013393. Blood Adv. 2024. PMID: 38861344 Free PMC article.
Conventional and novel [18F]FDG PET/CT features as predictors of CAR-T cell therapy outcome in large B-cell lymphoma.
Leithner D, Flynn JR, Devlin SM, Mauguen A, Fei T, Zeng S, Zheng J, Imber BS, Hubbeling H, Mayerhoefer ME, Bedmutha A, Luttwak E, Corona M, Dahi PB, Luna de Abia A, Landego I, Lin RJ, Palomba ML, Scordo M, Park JH, Tomas AA, Salles G, Lafontaine D, Michaud L, Shah GL, Perales MA, Shouval R, Schöder H. Leithner D, et al. Among authors: luna de abia a. J Hematol Oncol. 2024 Apr 23;17(1):21. doi: 10.1186/s13045-024-01540-x. J Hematol Oncol. 2024. PMID: 38649972 Free PMC article.
Provirus reactivation is impaired in HIV-1 infected individuals on treatment with dasatinib and antiretroviral therapy.
Vigón L, Martínez-Román P, Rodríguez-Mora S, Torres M, Puertas MC, Mateos E, Salgado M, Navarro A, Sánchez-Conde M, Ambrosioni J, Cervero M, Wyen C, Hoffmann C, Miró JM, Alcamí J, Podzamczer D, García-Gutiérrez V, Martínez-Picado J, Briz V, Rosa López-Huertas M, Planelles V, Coiras M; Multidisciplinary Group of Study of HIV-1 Reservoir MGS-HIVRES. Vigón L, et al. Biochem Pharmacol. 2021 Oct;192:114666. doi: 10.1016/j.bcp.2021.114666. Epub 2021 Jun 26. Biochem Pharmacol. 2021. PMID: 34186065 Free PMC article.